Logo image of MRX.DE

MISTER SPEX SE (MRX.DE) Stock Fundamental Analysis

FRA:MRX - Deutsche Boerse Ag - DE000A3CSAE2 - Common Stock - Currency: EUR

1.925  -0.03 (-1.53%)

Fundamental Rating

2

Taking everything into account, MRX scores 2 out of 10 in our fundamental rating. MRX was compared to 51 industry peers in the Specialty Retail industry. Both the profitability and financial health of MRX have multiple concerns. MRX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MRX has reported negative net income.
MRX had a negative operating cash flow in the past year.
In the past 5 years MRX always reported negative net income.
In the past 5 years MRX reported 4 times negative operating cash flow.
MRX.DE Yearly Net Income VS EBIT VS OCF VS FCFMRX.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

With a Return On Assets value of -50.10%, MRX is not doing good in the industry: 88.24% of the companies in the same industry are doing better.
With a Return On Equity value of -125.35%, MRX is not doing good in the industry: 88.24% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -50.1%
ROE -125.35%
ROIC N/A
ROA(3y)-27.31%
ROA(5y)-20%
ROE(3y)-57.09%
ROE(5y)-43%
ROIC(3y)N/A
ROIC(5y)N/A
MRX.DE Yearly ROA, ROE, ROICMRX.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

Looking at the Gross Margin, with a value of 51.82%, MRX is in the better half of the industry, outperforming 78.43% of the companies in the same industry.
In the last couple of years the Gross Margin of MRX has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for MRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 51.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y0.94%
MRX.DE Yearly Profit, Operating, Gross MarginsMRX.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

More info and screens

3

2. Health

2.1 Basic Checks

MRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MRX has more shares outstanding
The number of shares outstanding for MRX has been increased compared to 5 years ago.
The debt/assets ratio for MRX is higher compared to a year ago.
MRX.DE Yearly Shares OutstandingMRX.DE Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
MRX.DE Yearly Total Debt VS Total AssetsMRX.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -2.06, we must say that MRX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -2.06, MRX is not doing good in the industry: 76.47% of the companies in the same industry are doing better.
MRX has a Debt/Equity ratio of 0.79. This is a neutral value indicating MRX is somewhat dependend on debt financing.
MRX has a Debt to Equity ratio (0.79) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Altman-Z -2.06
ROIC/WACCN/A
WACC5.2%
MRX.DE Yearly LT Debt VS Equity VS FCFMRX.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

MRX has a Current Ratio of 2.47. This indicates that MRX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.47, MRX belongs to the top of the industry, outperforming 86.27% of the companies in the same industry.
A Quick Ratio of 1.82 indicates that MRX should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.82, MRX belongs to the top of the industry, outperforming 90.20% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.47
Quick Ratio 1.82
MRX.DE Yearly Current Assets VS Current LiabilitesMRX.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

5

3. Growth

3.1 Past

MRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -66.36%.
Looking at the last year, MRX shows a decrease in Revenue. The Revenue has decreased by -6.33% in the last year.
Measured over the past years, MRX shows a quite strong growth in Revenue. The Revenue has been growing by 9.25% on average per year.
EPS 1Y (TTM)-66.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.59%
Revenue 1Y (TTM)-6.33%
Revenue growth 3Y3.73%
Revenue growth 5Y9.25%
Sales Q2Q%-12.55%

3.2 Future

The Earnings Per Share is expected to grow by 22.39% on average over the next years. This is a very strong growth
MRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.67% yearly.
EPS Next Y49.5%
EPS Next 2Y30.58%
EPS Next 3Y22.39%
EPS Next 5YN/A
Revenue Next Year-12.04%
Revenue Next 2Y-4.76%
Revenue Next 3Y-1.73%
Revenue Next 5Y11.67%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MRX.DE Yearly Revenue VS EstimatesMRX.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M
MRX.DE Yearly EPS VS EstimatesMRX.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRX.DE Price Earnings VS Forward Price EarningsMRX.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRX.DE Per share dataMRX.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

MRX's earnings are expected to grow with 22.39% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.58%
EPS Next 3Y22.39%

More info and screens

0

5. Dividend

5.1 Amount

MRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MISTER SPEX SE

FRA:MRX (8/1/2025, 7:00:00 PM)

1.925

-0.03 (-1.53%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustrySpecialty Retail
Earnings (Last)05-08 2024-05-08/amc
Earnings (Next)N/A N/A
Inst Owners24.87%
Inst Owner ChangeN/A
Ins Owners3.98%
Ins Owner ChangeN/A
Market Cap67.47M
Analysts77.5
Price Target4.18 (117.14%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.2%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-4.91%
Revenue NY rev (3m)-4.91%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.32
P/FCF N/A
P/OCF N/A
P/B 1.03
P/tB 1.13
EV/EBITDA N/A
EPS(TTM)-2.48
EYN/A
EPS(NY)-0.45
Fwd EYN/A
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS6
BVpS1.87
TBVpS1.7
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -50.1%
ROE -125.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 51.82%
FCFM N/A
ROA(3y)-27.31%
ROA(5y)-20%
ROE(3y)-57.09%
ROE(5y)-43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y0.94%
F-Score2
Asset Turnover1.29
Health
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.67%
Cap/Sales 2.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.47
Quick Ratio 1.82
Altman-Z -2.06
F-Score2
WACC5.2%
ROIC/WACCN/A
Cap/Depr(3y)41.44%
Cap/Depr(5y)71.03%
Cap/Sales(3y)6.28%
Cap/Sales(5y)7.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-66.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.59%
EPS Next Y49.5%
EPS Next 2Y30.58%
EPS Next 3Y22.39%
EPS Next 5YN/A
Revenue 1Y (TTM)-6.33%
Revenue growth 3Y3.73%
Revenue growth 5Y9.25%
Sales Q2Q%-12.55%
Revenue Next Year-12.04%
Revenue Next 2Y-4.76%
Revenue Next 3Y-1.73%
Revenue Next 5Y11.67%
EBIT growth 1Y-66.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year96.97%
EBIT Next 3Y32.58%
EBIT Next 5Y29.96%
FCF growth 1Y60.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y52.14%
OCF growth 3YN/A
OCF growth 5YN/A